CN101080487B - 成熟树突细胞组合物及其培养方法 - Google Patents

成熟树突细胞组合物及其培养方法 Download PDF

Info

Publication number
CN101080487B
CN101080487B CN2005800337404A CN200580033740A CN101080487B CN 101080487 B CN101080487 B CN 101080487B CN 2005800337404 A CN2005800337404 A CN 2005800337404A CN 200580033740 A CN200580033740 A CN 200580033740A CN 101080487 B CN101080487 B CN 101080487B
Authority
CN
China
Prior art keywords
cells
cd40l
cell
dendritic cell
dcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800337404A
Other languages
English (en)
Chinese (zh)
Other versions
CN101080487A (zh
Inventor
D·赫利
I·切雷帕诺瓦
M·亚当斯
A·希诺哈拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merix Bioscience Inc
Original Assignee
Kirin Brewery Co Ltd
Merix Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery Co Ltd, Merix Bioscience Inc filed Critical Kirin Brewery Co Ltd
Publication of CN101080487A publication Critical patent/CN101080487A/zh
Application granted granted Critical
Publication of CN101080487B publication Critical patent/CN101080487B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2005800337404A 2004-10-07 2005-10-07 成熟树突细胞组合物及其培养方法 Expired - Fee Related CN101080487B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52251204P 2004-10-07 2004-10-07
US60/522,512 2004-10-07
PCT/US2005/036304 WO2006042177A2 (en) 2004-10-07 2005-10-07 Mature dendritic cell compositions and methods for culturing same

Publications (2)

Publication Number Publication Date
CN101080487A CN101080487A (zh) 2007-11-28
CN101080487B true CN101080487B (zh) 2012-11-14

Family

ID=36148973

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800337404A Expired - Fee Related CN101080487B (zh) 2004-10-07 2005-10-07 成熟树突细胞组合物及其培养方法

Country Status (13)

Country Link
US (4) US20080145931A1 (enExample)
EP (2) EP1809737B9 (enExample)
JP (2) JP5269412B2 (enExample)
KR (1) KR101243577B1 (enExample)
CN (1) CN101080487B (enExample)
AT (1) ATE489455T1 (enExample)
AU (1) AU2005294150B2 (enExample)
CA (1) CA2577125C (enExample)
DE (1) DE602005025005D1 (enExample)
DK (1) DK1809737T3 (enExample)
ES (1) ES2861199T3 (enExample)
TW (1) TWI382843B (enExample)
WO (1) WO2006042177A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
US8513008B2 (en) * 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
AU2006249640C1 (en) 2005-04-08 2016-10-13 Coimmune, Inc. Dendritic cell compositions and methods
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP2517723B1 (en) 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
DE102007006736B4 (de) 2007-02-07 2012-01-12 Dagmar Briechle In-vitro Testkit zur tierversuchsfreien Bestimmung des sensibilisierenden Potentials einer Substanz
WO2008133983A1 (en) * 2007-04-25 2008-11-06 Immurx, Inc. Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity
PT2201100E (pt) * 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
EP3173474A1 (en) * 2007-09-14 2017-05-31 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
US9408909B2 (en) 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
WO2009145853A1 (en) * 2008-04-16 2009-12-03 Virostatics Srl Novel assay for precursor t-cells having high proliferative capacity (phpc-assay)
WO2010055900A1 (ja) 2008-11-14 2010-05-20 ディナベック株式会社 樹状細胞の製造方法
MX2011005915A (es) 2008-12-03 2011-08-17 Proyecto Biomedicina Cima Sl Uso de modulinas solubles en fenol para el desarrollo de vacunas.
CN102753700A (zh) * 2009-09-04 2012-10-24 先正达参股股份有限公司 增加植物中多肽表达的翻译增强子元件堆叠
BR112012014104A2 (pt) * 2009-12-04 2016-07-05 Stem Cell & Regenerative Medicine International Inc método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
BR112014014591A8 (pt) * 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR102402451B1 (ko) * 2013-03-28 2022-05-26 더 유니버시티 오브 브리티쉬 콜롬비아 미세유동 장치 및 분비물의 다세포 검정법에서의 그의 사용 방법
JP2016081562A (ja) 2014-10-09 2016-05-16 ソニー株式会社 表示装置、表示装置の製造方法および電子機器
WO2016145317A1 (en) * 2015-03-12 2016-09-15 Thomas Schwaab Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality
CN105670994A (zh) * 2016-02-28 2016-06-15 深圳爱生再生医学科技有限公司 Dc诱导剂及其应用
CN118165113B (zh) * 2016-04-26 2025-10-28 恺兴生命科技(上海)有限公司 一种改善免疫应答细胞功能的方法
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
JP2021502419A (ja) 2017-11-07 2021-01-28 コイミューン インコーポレイテッド 樹状細胞治療のための方法および使用
JP7493497B2 (ja) * 2018-06-19 2024-05-31 フォンダッツィオーネ・テレソン・エティエッセ 操作された樹状細胞の生産及びその使用
CA3106403A1 (en) * 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
CN109797209B (zh) * 2019-01-04 2021-07-16 中国人民解放军第二军医大学 一种树突状细胞和/或趋化性树突状细胞和/或其趋化状态和功能的特异性生物标志物
US12618074B2 (en) 2019-04-11 2026-05-05 The Board Of Trustees Of The University Of Arkansas CD40 specific DNA aptamers as vaccine adjuvants
MX2021015643A (es) * 2019-06-17 2022-04-06 Enochian Biopharma Inc Vacuna alogénica contra el virus de inmunodeficiencia humana (vih) basada en linfocitos t para inducir la inmunidad celular y humoral.
AU2024356278A1 (en) * 2023-10-05 2026-02-26 Amgen Inc. Major histocompatibility complex (mhc)-associated peptide proteomics (mapps) assay for immunogenicity risk assessment of biotherapeutic attributes
WO2025147510A1 (en) * 2024-01-05 2025-07-10 Renovaro Biopharma Inc. Methods and compositions using recombinant dendritic cells for cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1522264A (zh) * 2001-04-27 2004-08-18 麒麟麦酒株式会社 抗cd40单克隆抗体

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3424893A1 (de) 1984-07-06 1986-02-06 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches silberhalogenidaufzeichnungsmaterial
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068910B2 (ja) 1990-11-08 2000-07-24 麒麟麦酒株式会社 新規スフィンゴ糖脂質、その製造法および使用
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
EP0563485A1 (en) 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
TW261533B (enExample) 1992-07-16 1995-11-01 Kirin Brewery
ATE191916T1 (de) 1992-10-22 2000-05-15 Kirin Brewery Neues sphingolglycolipid und verwendung davon
US5780441A (en) 1993-04-15 1998-07-14 Kirin Beer Kabushiki Kaisha Sphingoglycolipid compounds and therapeutic uses thereof
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
PL181496B1 (pl) 1996-03-20 2001-07-31 Politechnika Slaska Im Wincent Sposób wytwarzania ß-naftolu PL
KR20000022445A (ko) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
US6017527A (en) 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
EP1520583B1 (en) 1997-04-10 2009-01-28 Kyowa Hakko Kirin Co., Ltd. NKT cell-activating agents containing alpha-glycosylceramides
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
EP1079854B1 (en) 1998-05-26 2009-04-15 Genitrix LLC Compositions and methods of modulating an immune response to an antigen by administration of cytokine-coated cells
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
WO2000073432A2 (en) * 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
WO2001016180A2 (en) * 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
US20030077263A1 (en) 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
EP1297017B1 (en) 2000-06-19 2012-06-13 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
WO2002036141A2 (en) * 2000-11-02 2002-05-10 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
AU2002224851A1 (en) 2000-11-14 2002-05-27 Universite Libre De Bruxelles Generation and use of dendritic cells
FR2819263B1 (fr) 2001-01-10 2003-04-11 Lco Sante Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740
ES2254527T3 (es) 2001-01-15 2006-06-16 I.D.M. Immuno-Designed Molecules Metodo para la preparacion de suspensiones de particulas submicronicas de agentes farmaceuticos.
US7767202B2 (en) 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
EP1270732A1 (en) 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US20040241147A1 (en) * 2001-07-25 2004-12-02 Alessandra Nardin New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions
US20040072347A1 (en) 2001-07-27 2004-04-15 Gerold Schuler Generation of fully mature and stable dendritic cells from leukaphereses products for clinical applications
AU2002327097B2 (en) 2001-08-16 2007-05-24 Japan As Represented By President Of National Centre Of Neurology And Psychiatry Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
US20030153073A1 (en) * 2001-11-07 2003-08-14 Paul Rogers Expansion of T cells in vitro and expanded T cell populations
WO2003105769A2 (en) 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
AU2003295331A1 (en) * 2002-09-19 2004-04-23 Centocor, Inc. Method of inducing maturation of dendritic cells and uses therefor
KR20050062551A (ko) 2002-09-20 2005-06-23 기린 비루 가부시키가이샤 α-글리코실세라미드를 유효 성분으로 하는 Ｃ형 간염 바이러스 억제제
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
US20060239962A1 (en) 2002-12-04 2006-10-26 Banchereau Jacques F Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors
WO2004053095A2 (en) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
US20050003533A1 (en) * 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
US7060111B2 (en) 2003-07-03 2006-06-13 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Method for providing more vibrant, natural and long-lasting color to hair
CA2560969A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1522264A (zh) * 2001-04-27 2004-08-18 麒麟麦酒株式会社 抗cd40单克隆抗体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Richard C. Koya et al.Potent Maturation of Monocyte-Derived Dendritic Cells AfterCD40L Lentiviral Gene Delivery.Journal of Immunotherapy26 5.2003,452-458页.
Richard C. Koya et al.Potent Maturation of Monocyte-Derived Dendritic Cells AfterCD40L Lentiviral Gene Delivery.Journal of Immunotherapy26 5.2003,452-458页. *
张建芳等.树突状细胞的体外培养及其诱导的抗肿瘤免疫作用.第四军医大学学报22 19.2001,22(19),1779页左栏第1段.
张建芳等.树突状细胞的体外培养及其诱导的抗肿瘤免疫作用.第四军医大学学报22 19.2001,22(19),1779页左栏第1段. *
汪晓莺等.细胞因子诱导慢性乙型肝炎患者树突状细胞的免疫功能.世界华人消化杂志11 12.2003,11(12),1871页表2,1871页材料和方法部分.
汪晓莺等.细胞因子诱导慢性乙型肝炎患者树突状细胞的免疫功能.世界华人消化杂志11 12.2003,11(12),1871页表2,1871页材料和方法部分. *

Also Published As

Publication number Publication date
WO2006042177A2 (en) 2006-04-20
US20170096640A1 (en) 2017-04-06
JP2008515439A (ja) 2008-05-15
CA2577125C (en) 2016-01-12
ATE489455T1 (de) 2010-12-15
TWI382843B (zh) 2013-01-21
CN101080487A (zh) 2007-11-28
KR101243577B1 (ko) 2013-03-20
EP1809737B9 (en) 2011-10-05
JP5269412B2 (ja) 2013-08-21
HK1105997A1 (en) 2008-02-29
US20080145931A1 (en) 2008-06-19
US11248209B2 (en) 2022-02-15
US20060078994A1 (en) 2006-04-13
AU2005294150A1 (en) 2006-04-20
CA2577125A1 (en) 2006-04-20
WO2006042177A3 (en) 2007-02-01
EP2251418A1 (en) 2010-11-17
KR20070101233A (ko) 2007-10-16
TW200630491A (en) 2006-09-01
US20150072431A1 (en) 2015-03-12
EP1809737B1 (en) 2010-11-24
US8822223B2 (en) 2014-09-02
EP2251418B1 (en) 2021-03-17
AU2005294150B2 (en) 2011-06-16
DK1809737T3 (da) 2011-03-07
ES2861199T3 (es) 2021-10-06
US9556455B2 (en) 2017-01-31
DE602005025005D1 (de) 2011-01-05
JP2013121352A (ja) 2013-06-20
EP1809737A2 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
US11248209B2 (en) Mature dendritic cell compositions and methods for culturing same
JP5425618B2 (ja) 成熟樹状細胞組成物およびそれを培養するための方法
EP3107996B1 (en) Tscm cells and methods for use
HK1144588A (en) Mature dendritic cell compositions and methods for culturing same
HK1105997B (en) Mature dendritic cell compositions and methods for culturing same
HK1144588B (en) Mature dendritic cell compositions and methods for culturing same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20091023

Address after: North Carolina

Applicant after: Argos Therapeutics, Inc.

Co-applicant after: Kyowa Hakko Kirin Co.,Ltd.

Address before: North Carolina

Applicant before: Argos Therapeutics, Inc.

Co-applicant before: KIRIN HOLDINGS Kabushiki Kaisha

ASS Succession or assignment of patent right

Free format text: FORMER OWNER: KYOWA HAKKO KIRIN CO., LTD.

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20101009

Address after: North Carolina

Applicant after: Argos Therapeutics, Inc.

Address before: North Carolina

Applicant before: Argos Therapeutics, Inc.

Co-applicant before: Kyowa Hakko Kirin Co.,Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20071128

Assignee: Lummy (Hongkong) Co. Ltd.

Assignor: Argos Therapeutics, Inc.

Contract record no.: 2015990001055

Denomination of invention: Mature dendritic cell compositions and methods for culturing same

Granted publication date: 20121114

License type: Exclusive License

Record date: 20151218

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121114

CF01 Termination of patent right due to non-payment of annual fee